Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Tumor protein p53 (TP53) is the most frequently mutated gene in cancer1,2. In patients with myelodysplastic syndromes (MDS), TP53 mutations are associated with high-risk disease3,4, rapid transformation to acute myeloid leukemia (AML)5, resistance to conventional therapies6,7,8 and dismal outcomes9....

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Bernard, E, Nannya, Y, Hasserjian, RP, Boultwood, J, Pellagatti, A
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	Springer Nature 2020

Gelijkaardige items

NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
door: Fidler, C, et al.
Gepubliceerd in: (2004)

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
door: Ramy Rahmé, et al.
Gepubliceerd in: (2023-04-01)

Rare case of myelodysplastic syndrome with near-tetraploidy and TP53 mutation
door: Čolović Nataša, et al.
Gepubliceerd in: (2023-01-01)

Clinical outcomes and characteristics of patients with TP53-mutated myelodysplastic syndromes
door: Lijuan Zhang, et al.
Gepubliceerd in: (2023-12-01)

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
door: Haase, D, et al.
Gepubliceerd in: (2019)

SF3B1 mutant myelodysplastic syndrome: Recent advances
door: Pellagatti, A, et al.
Gepubliceerd in: (2020)

TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
door: Pimjai Niparuck, et al.
Gepubliceerd in: (2021-10-01)

Gene expression profiling in the myelodysplastic syndromes.
door: Pellagatti, A, et al.
Gepubliceerd in: (2005)

Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
door: Pellagatti, A, et al.
Gepubliceerd in: (2016)

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
door: Davidson Zhao, et al.
Gepubliceerd in: (2023-03-01)

The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes.
door: Boultwood, J, et al.
Gepubliceerd in: (2014)

TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions
door: Daver, NG, et al.
Gepubliceerd in: (2022)

Single-molecule DNA sequencing of acute myeloid leukemia and myelodysplastic syndromes with multiple TP53 alterations
door: Laurence Lodé, et al.
Gepubliceerd in: (2018-01-01)

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis
door: Rashmi Kanagal-Shamanna, et al.
Gepubliceerd in: (2021-03-01)

A tale of two alleles: TP53 and transformation in MPNs
door: Brierley, C, et al.
Gepubliceerd in: (2022)

High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation
door: Liberante, F, et al.
Gepubliceerd in: (2013)

High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation.
door: Liberante, F, et al.
Gepubliceerd in: (2013)

Transplantation for therapy-related, TP53-mutated myelodysplastic syndrome – not because we can, but because we should
door: Corey Cutler
Gepubliceerd in: (2017-12-01)

Presence of new mutations in the TP53 gene in patients with low-risk myelodysplastic syndrome: two case reports
door: Fernando Barroso Duarte, et al.
Gepubliceerd in: (2017-05-01)

Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches
door: Armstrong, R, et al.
Gepubliceerd in: (2017)

Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen
door: Nikeeta Mandhan, et al.
Gepubliceerd in: (2022-01-01)

Clonality in the myelodysplastic syndromes.
door: Boultwood, J, et al.
Gepubliceerd in: (2001)

To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia
door: David A. Sallman
Gepubliceerd in: (2020-06-01)

PB1913: SYNERGISTIC EFFECTS OF DECITABINE AND APR-246 IN TP53 P.248Q-MUTATED MYELODYSPLASTIC SYNDROME
door: Y. Fang, et al.
Gepubliceerd in: (2022-06-01)

Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions
door: Shyam A. Patel, et al.
Gepubliceerd in: (2023-11-01)

Pulmonary infection associated with immune dysfunction is associated with poor prognosis in patients with myelodysplastic syndrome accompanied by TP53 abnormalities
door: Yi Chen, et al.
Gepubliceerd in: (2023-11-01)

Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia
door: Kathy L. McGraw, et al.
Gepubliceerd in: (2016-08-01)

Molecular pathogenesis of the myelodysplastic syndromes
door: Boultwood, J, et al.
Gepubliceerd in: (1999)

Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome.
door: Boultwood, J, et al.
Gepubliceerd in: (2012)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
door: Melania Tesio
Gepubliceerd in: (2023-02-01)

Telomere length in myelodysplastic syndromes.
door: Boultwood, J, et al.
Gepubliceerd in: (1995)

Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia
door: Nabih Maslah, et al.
Gepubliceerd in: (2020-06-01)

Allogeneic haematopoietic stem cell transplantation with decitabine-containing preconditioning regimen in TP53-mutant myelodysplastic syndromes: A case study
door: Yuxin Wang, et al.
Gepubliceerd in: (2022-07-01)

Gene expression profiling in 5q-syndrome and myelodysplastic syndromes.
door: Pellagatti, A, et al.
Gepubliceerd in: (2003)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
door: Haiwei Wang, et al.
Gepubliceerd in: (2022-06-01)

The role and impact of Del(5q) and TP53 mutations on haematopoietic stem and progenitor cells during the progression of Myelodysplastic Syndrome to Acute Myeloid Leukaemia
door: Doolittle, H
Gepubliceerd in: (2017)

Genomic Characterization of TP53–Wild-Type Esophageal Carcinoma
door: Alexander Quaas, et al.
Gepubliceerd in: (2019-01-01)

Gene Expression Profiling of CD34(+) Cells in Patients with Myelodysplastic Syndromes
door: Pellagatti, A, et al.
Gepubliceerd in: (2008)

P066: Variant overlooked: A partial deficiency TP53 allele that skirts interpretation criteria
door: Lisa Lansdon, et al.
Gepubliceerd in: (2023-01-01)

Clinical and biological implications of driver mutations in myelodysplastic syndromes.
door: Papaemmanuil, E, et al.
Gepubliceerd in: (2013)